These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31062695)

  • 1. Late structural discontinuity after bioresorbable vascular scaffold implantation in patients with in-stent restenosis.
    Cuesta J; Antuña P; Bastante T; Alfonso F
    EuroIntervention; 2021 Jan; 16(13):1104-1105. PubMed ID: 31062695
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial.
    Arroyo D; Togni M; Puricel S; Gerard B; Sonja L; Corpataux N; Villeneuve H; Boute E; Stauffer JC; Goy JJ; Cook S
    Trials; 2014 Jan; 15():9. PubMed ID: 24398143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late stent thrombosis after the use of a bioresorbable vascular scaffold for the treatment of in-stent restenosis.
    Lee WC; Fang HY; Fang CY
    Coron Artery Dis; 2016 Dec; 27(8):709-710. PubMed ID: 27379437
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-Stent Restenosis: Is the Future Bioresorbable?
    Claessen BE; Feldman DN
    JACC Cardiovasc Interv; 2024 Aug; 17(15):1837-1839. PubMed ID: 39142759
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance.
    Zuk G; Ciecwierz D; Drewla P; Gruchała M; Gutiérrez-Chico JL; Jaguszewski M
    Cardiol J; 2019; 26(3):304-306. PubMed ID: 31246271
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
    Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis.
    Moscarella E; Ielasi A; Cortese B; De Angelis MC; Varricchio A
    Coron Artery Dis; 2017 Aug; 28(5):437-439. PubMed ID: 28574901
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioresorbable scaffolds for the treatment of in-stent restenosis.
    Dörr O; Liebetrau C; Wiebe J; Hecker F; Rixe J; Möllmann H; Hamm C; Nef H
    Heart Vessels; 2015 Mar; 30(2):265-9. PubMed ID: 24390727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.
    Madanchi M; Cioffi GM; Attinger-Toller A; Wolfrum M; Moccetti F; Seiler T; Vercelli L; Burkart P; Toggweiler S; Kobza R; Bossard M; Cuculi F
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34518287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioresorbable scaffold failure for recurrent restenosis at multi-layered stent fracture.
    Tanaka A; Jabbour RJ; Kawamoto H; Latib A; Colombo A
    Int J Cardiol; 2016 Jul; 214():360-1. PubMed ID: 27085648
    [No Abstract]   [Full Text] [Related]  

  • 15. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoatherosclerosis: an emerging and conceptually unexpected cause of very late bioresorbable vascular scaffold failure.
    Hiltrop N; Desmet W; Adriaenssens T; Bennett J
    EuroIntervention; 2017 Mar; 12(16):2031. PubMed ID: 28317791
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.